NCT04371796 2020-05-01
Sintilimab (IBI308) in the Neoadjuvant Treatment of Patients With Resectable II-IIIA NSCLC
Sichuan Cancer Hospital and Research Institute
Phase 2 Unknown
Sichuan Cancer Hospital and Research Institute
Sichuan Cancer Hospital and Research Institute